Fioricet Oral and Tazarotene

• Generic Name: acetaminophen / butalbital / caffeine
• Dosage Forms: tablet
• Other Brand Names: Capacet, Esgic, Fioricet, Margesic, Medigesic, Orbivan, Repan, Vanatol LQ, Zebutal, Esgic-Plus, Arcet, Isocet, Pharmagesic, Anoquan, Two-Dyne, Tenake, Anolor 300, Femcet, Geone, Tencet, Triad, Fiorpap, Dolmar, Endolor, Ezol, Ide-cet, G-1, Minotal, Mygracet, Pacaps, Alagesic, Americet, Nonbac, Dolgic LQ, Dolgic Plus, Vanatol S, Alagesic LQ

Butalbital, acetaminophen, and caffeine combination is used to relieve symptoms of tension (or muscle contraction) headaches.

Butalbital belongs to the group of medicines called barbiturates. Barbiturates act in the central nervous system (CNS) to produce their effects.

Acetaminophen is used to relieve pain and reduce fever in patients. It does not become habit-forming when taken for a long time. But acetaminophen may cause other unwanted effects when taken in large doses, including liver damage.

When butalbital is used for a long time, it may become habit-forming, causing mental or physical dependence. However, people who have continuing pain should not let the fear of dependence keep them from using narcotics to relieve their pain. Physical dependence may lead to withdrawal side effects if treatment is stopped suddenly. However, severe withdrawal side effects can usually be prevented by gradually reducing the dose over a period of time before treatment is stopped completely.

Caffeine is a CNS stimulant that is used with pain relievers to increase their effect. It has also been used for migraine headaches. However, caffeine can also cause physical dependence when it is used for a long time. This may lead to withdrawal (rebound) headaches when you stop taking it.

This medicine is available only with your doctor's prescription.

• Generic Name: tazarotene topical
• Dosage Forms: n.a.
• Other Brand Names: Avage, Fabior, Tazorac

Treatment of stable plaque psoriasis with ≤20% body surface area involvement.

Combination therapy with a mid-or high-potency topical corticosteroid more effective than either agent alone.

0.1% cream or gel more effective in improving psoriasis manifestations; 0.05% cream or gel associated with less local irritation.

Treatment of mild to moderate acne vulgaris.

Efficacy in patients resistant to oral antibiotics or previously treated with other retinoids not established.

Palliative therapy to improve dermatologic changes (e.g., fine wrinkling, mottled hypo- or hyperpigmentation, benign lentigines) associated with photodamage.

Use as an adjunct to a comprehensive skin care plan and sun avoidance program. (See Administration under Dosage and Administration.)

Does not eliminate or prevent wrinkles, repair photodamaged skin, reverse photoaging, or restore youthful or younger dermal histologic pattern. No mitigating effects on severe manifestations of chronic sunlight exposure (e.g., coarse/deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, dermal elastosis) demonstrated.

Safety and efficacy not established for use in nonwhite (e.g., Asian, Hispanic) patients or Fitzpatrick skin types V and VI.